New Drug Target for Remyelination in Multiple Sclerosis

Updated August 15, 2018 This content is archived.

Research by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology has found that a receptor called muscarinic type 3 (M3R), a key regulator of the remyelination process, is a promising drug target in the treatment of multiple sclerosis. “This work establishes that M3R has a functional role and if blocked, could improve myelin repair,” he said. “It better positions the field for clinical trials that will be aimed at blocking these receptors in MS patients.”